cyclopentane has been researched along with oseltamivir in 133 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 23 (17.29) | 29.6817 |
| 2010's | 102 (76.69) | 24.3611 |
| 2020's | 8 (6.02) | 2.80 |
| Authors | Studies |
|---|---|
| Babu, YS; Bailey, KW; Barnard, DL; Huffman, JH; Morrey, JD; Sidwell, RW; Smee, DF | 1 |
| Ananth, SL; Andries, K; Babu, YS; Bantia, S; Chand, P; Dehghani, A; El-Kattan, Y; Horn, LL; Hutchison, TL; Kellog, DL; Kotian, PL; Lin, T; Montgomery, JA; Parker, CD | 1 |
| Bush, K; Goloubeva, OG; Govorkova, EA; Leneva, IA; Webster, RG | 1 |
| Gubareva, LV; Hayden, FG; Webster, RG | 2 |
| Gubareva, LV; Hayden, FG; Nedyalkova, MS; Webster, RG | 1 |
| Babu, YS; Bush, K; Chand, P; Desai-Krieger, D; Jakeman, KJ; McKown, LA; Streeter, AJ; Sweet, C; Wagaman, PC | 1 |
| Colman, PM; Fernley, RT; McDonald, M; McKimm-Breshkin, JL; Smith, BJ; Varghese, JN | 1 |
| Boivin, G; Goyette, N | 1 |
| Barr, IG; Hampson, AW; Hurt, AC; Komadina, N; McDonald, M; McKimm-Breschkin, JL | 1 |
| Abed, Y; Boivin, G; Goyette, N | 1 |
| Babu, YS; Bantia, S; Chand, P; El-Kattan, Y; Kotian, PL; Lin, TH | 1 |
| Barr, IG; Hampson, AW; Hurt, AC; Iannello, P; Jachno, K; Komadina, N; McKimm-Breschkin, JL | 1 |
| Abed, Y; Baz, M; Boivin, G; McDonald, J | 1 |
| Barr, IG; Brown, L; Hurt, AC; Komadina, N; Selleck, P; Shaw, R | 1 |
| Abed, Y; Baz, M; Boivin, G | 2 |
| Reina, J | 1 |
| Reece, PA | 2 |
| Aruksakunwong, O; Decha, P; Hannongbua, S; Intharathep, P; Malaisree, M; Rungrotmongkol, T | 1 |
| Arnold, CS; Barr, IG; Dziuba, N; Holbrook, MR; Hurt, AC; Kilpatrick, JM; Linde, NS; Paessler, S; Smith, JN; Yun, NE; Zacks, MA; Zhang, L | 1 |
| Barr, IG; Besselaar, TG; Birch, C; Buchy, P; Chittaganpitch, M; Chiu, SC; D'Souza, H; Deng, YM; Dwyer, D; Ernest, J; Guigon, A; Harrower, B; Hurt, AC; Iannello, P; Kei, IP; Kelso, A; Kok, T; Komadina, N; Lin, C; McPhie, K; Mohd, A; Olveda, R; Panayotou, T; Rawlinson, W; Scott, L; Shaw, R; Smith, D | 1 |
| Bren, U; Frecer, V; Rungrotmongkol, T; Stanislav, M; Udommaneethanakit, T | 1 |
| Deyde, VM; Garten, RJ; Gubareva, LV; Klimov, AI; Nguyen, HT; Okomo-Adhiambo, M; Shaw, MW; Sheu, TG; Sleeman, K; Xu, X | 1 |
| Eichelberger, MC; Hassantoufighi, A; Hrabal, RJ; Memoli, MJ; Taubenberger, JK | 1 |
| Davey, RT; Fang, F; Moss, RB; Steigbigel, RT | 1 |
| Boltz, DA; Castillo, R; Holland, LE | 1 |
| Gubareva, LV; Klimov, AI; Mishin, VP; Nguyen, HT; Sheu, TG | 1 |
| Babu, YS; Hurst, BL; Klumpp, K; Morrey, JD; Smee, DF; Tarbet, EB; Wong, MH | 1 |
| DeLiberto, T; DuBois, RM; Govorkova, EA; Gramer, MR; Krauss, S; Negovetich, NJ; Senne, DA; Stallknecht, DE; Stoner, TD; Swafford, S; Webster, RG | 1 |
| Barrett, S; McKimm-Breschkin, JL; Newman, J; Oakley, AJ; Peat, TS; Saito, T; Streltsov, VA; Tashiro, M; Waddington, L | 1 |
| Fu, Y; Nie, Y; Yang, G; Yang, Z; Zhou, L; Zu, Y | 1 |
| Ishii, H; Kadota, J; Tokimatsu, I; Yoshioka, D | 1 |
| Boeckh, MJ; Corey, L; Englund, JA; Jain, R; Kuypers, J; Pergam, SA; Polyak, C; Renaud, C | 1 |
| Abed, Y; Boivin, G; Bouhy, X; Pizzorno, A | 1 |
| Deyde, VM; Fry, AM; Garten, RJ; Gubareva, LV; Klimov, AI; Mishin, VP; Nguyen, HT; Okomo-Adhiambo, M; Shaw, MW; Sheu, TG; Sleeman, K; Trujillo, AA | 1 |
| Adams, JR; Brown, AN; Drusano, GL; Kulawy, R; McSharry, JJ; Weng, Q | 1 |
| Li, JF; Shen, JS; Xiong, RS; Zhang, Q; Zhao, QJ | 1 |
| Babu, YS; Bantia, S; Upshaw, R | 1 |
| Adiga, RB; Alsup, R; Clay, PG; Gerk, PM; McRae, M; Taylor, TAH | 1 |
| Cheong, HJ; Hirotsu, N; Ishida, T; Kadota, J; Kida, H; Kohno, S; Mizuguchi, M; Shimada, J; Yen, MY | 1 |
| Barrett, S; McKimm-Breschkin, JL; Mohr, PG; Schmidt, PM | 1 |
| Atiee, G; Baughman, S; Collis, P; Hernandez, J; Hollister, A; Lasseter, K; McCullough, A | 1 |
| Fry, AM; Garg, S; Gubareva, LV; Kilpatrick, S; Moore, Z; Sheu, TG; Sleeman, K | 1 |
| Ghossein, C; Griffith, MM; Hollister, AS; Ison, MG; Scheetz, MH | 1 |
| Palmer, R | 1 |
| Abed, Y; Beaulieu, E; Boivin, G; Bouhy, X; Mallett, C; Pizzorno, A; Russell, R | 1 |
| Ikematsu, H; Kashiwagi, S; Kawai, N | 1 |
| Bastien, N; Beniprashad, M; Chong-King, E; Gubbay, JB; Higgins, RR; Li, Y; Low, DE | 1 |
| Barrett, S; McKimm-Breschkin, JL; Mohr, PG; Rootes, C; Streltsov, VA | 1 |
| Dapat, C; Dapat, IC; Kawashima, T; Kondo, H; Saito, K; Saito, R; Sato, I; Shobugawa, Y; Suzuki, H; Suzuki, Y | 1 |
| Abed, Y; Boivin, G; Pizzorno, A | 1 |
| Sakata, H | 1 |
| Feng, E; Hilgenfeld, R; Jiang, H; Li, J; Liu, H; Wang, J; Ye, D; Zhang, D; Zhao, F; Zheng, M | 1 |
| Alexander, WJ; Clezy, K; Collis, PJ; Flynt, A; Hui, DS; Ison, MG; O'Neil, BJ; Simon, TJ | 1 |
| Sato, R | 1 |
| Fujisaki, S; Imai, M; Kishida, N; Odagiri, T; Sato, H; Takashita, E; Taniwaki, T; Tashiro, M; Xu, H; Yokoyama, M | 1 |
| Itoh, Y; Kanazu, T; Kitano, M; Kobayashi, M; Kodama, M; Sato, A; Yoshida, R | 1 |
| Gubareva, LV; Klimov, AI; Li, Y; Lysén, C; Nguyen, HT; Okomo-Adhiambo, M; Sleeman, K; Xu, X | 1 |
| Chen, H; Guan, W; Hao, P; He, J; Hu, Y; Huang, K; Kang, B; Li, J; Li, T; Li, X; Li, Y; Liu, Y; Lu, S; Peiris, M; Ping, J; Shi, B; Song, Z; Tian, D; Wang, S; Wang, W; Xi, X; Xu, L; Yen, HL; Yuan, Z; Zha, L; Zhang, X; Zhang, Z; Zheng, L; Zhu, Z | 1 |
| Fujisaki, S; Imai, M; Kishida, N; Odagiri, T; Takashita, E; Tashiro, M; Xu, H | 1 |
| Barrett, S; Jachno, K; McDonald, M; McKimm-Breschkin, JL; Mohr, PG; Saito, T; Tashiro, M; Williams, J | 1 |
| Cheung, PP; Choy, KT; Guan, Y; McKimm-Breschkin, JL; Ng, IH; Peiris, JS; Webby, RJ; Webster, RG; Wong, DD; Yen, HL; Zhou, J; Zhu, H | 1 |
| Cao, B; Cao, RY; Kumaki, Y; Li, S; Xiao, JH; Zhong, W | 1 |
| Baranovich, T; Burnham, AJ; Govorkova, EA | 1 |
| Hou, T; Li, D; Li, L; Li, Y; Pan, P | 1 |
| Gubareva, LV; Guo, Z; Levine, M; Mishin, VP; Nguyen, HT; Okomo-Adhiambo, M; Sleeman, K; Stevens, J; Tamura, D; Xu, X; Yang, H | 1 |
| Cao, B; Hayden, FG | 1 |
| Louie, JK; Samuel, MC; Schechter, R; Uyeki, TM; Yang, S | 1 |
| Long, B; Malaisree, M; McIntosh-Smith, S; Mulholland, AJ; Woods, CJ | 1 |
| Ejima, M; Itoh, R; Miura, M; Nishimura, H; Odagiri, T; Ohnishi, A; Takashita, E; Tashiro, M | 1 |
| Balish, A; Fry, AM; Garten, RJ; Gubareva, LV; Guo, Z; Mishin, VP; Sleeman, K; Stevens, J; Villanueva, J | 1 |
| Homma, T; Imamura, Y; Iwanaga, N; Izumikawa, K; Kajihara, T; Kakeya, H; Kitano, M; Kohno, S; Kurihara, S; Miyazaki, T; Nakamura, S; Seki, M; Tanaka, A; Yanagihara, K | 1 |
| Kwoh, CK; Ouyang, X; Tran-To Su, C; Zheng, J | 1 |
| Kitazawa, T; Koga, I; Ota, Y; Seo, K; Yoshino, Y | 2 |
| Asai, T; Ichikawa, M; Ikezoe, I; Matsumoto, J; Miyagawa, S; Takemoto, Y; Yano, T | 1 |
| Bamba, M; Ichikawa, M; Ide, Y; Kawakami, C; Kawaoka, Y; Mitamura, K; Sakai-Tagawa, Y; Sugaya, N; Yamaguchi, Y; Yamazaki, M; Yasuhara, R | 1 |
| Barrett, S; McKimm-Breschkin, JL | 1 |
| Bae, JY; Baek, LJ; Cheong, HJ; Heo, J; Hwang, MW; Jang, SI; Kim, D; Kim, H; Kim, JI; Lee, I; Lee, S; Park, MS; Park, S; Song, JW; Song, KJ | 1 |
| Besselaar, T; Correia, V; Daniels, RS; Drager-Dayal, R; Fry, A; Gregory, V; Gubareva, L; Hurt, AC; Kageyama, T; Lackenby, A; Lo, J; Meijer, A; Odagiri, T; Pereyaslov, D; Rebelo-de-Andrade, H; Siqueira, MM; Takashita, E; Tashiro, M; Wang, D; Wong, S; Zhang, W | 1 |
| Bastien, N; Eshaghi, A; Gubbay, JB; Higgins, RR; Li, A; Li, Y; Rosenfeld, P; Rotstein, C; Savchenko, A; Shalhoub, S; Stogios, PJ | 1 |
| Ikematsu, H; Iwaki, N; Kashiwagi, S; Kawai, N | 2 |
| Ali, Z; Dapat, C; Dapat, IC; Dbaibo, G; Ghanem, S; Kayali, G; Kondo, H; Lteif, M; Saito, K; Saito, R; Suzuki, H; Zaraket, H | 1 |
| Baek, YH; Choi, YK; Kim, EH; Kim, MH; Kim, S; Kim, YI; Kwon, HI; Lee, EY; Lim, GJ; Park, KJ; Park, SJ; Pascua, PN; Song, MS; Webby, RJ; Yoon, SW | 1 |
| Cao, B; Chan, PK; Cheung, CS; Gu, L; Hui, DS; Kyaw, WM; Lee, N; Leo, YS; Li, H; Liu, Y; Liu, Z; Qu, J; Tam, WW; Uyeki, TM; Yung, IM | 1 |
| Fujisaki, S; Kawaoka, Y; Kiso, M; Nakamura, K; Odagiri, T; Sato, H; Shirakura, M; Takashita, E; Tashiro, M; Yokoyama, M | 1 |
| Ison, MG | 1 |
| Bahl, J; Baranovich, T; Culhane, M; Darnell, D; Govorkova, EA; Kaplan, BS; Lowe, JF; Marathe, BM; Stigger-Rosser, E; Webby, RJ | 1 |
| Besselaar, T; Daniels, RS; Fry, A; Gregory, V; Gubareva, L; Huang, W; Hurt, AC; Lackenby, A; Leang, SK; Lo, J; Mak, GC; Meijer, A; Pereyaslov, D; Rebelo-de-Andrade, H; Siqueira, MM; Takashita, E; Tashiro, M; Wang, D; Zhang, W | 1 |
| Homma, T; Kitano, M; Kobayashi, M; Naito, A; Onishi, M; Sato, A; Taniguchi, K; Yoshinaga, T | 1 |
| Campbell, AP; DeBiasi, RL; Fry, AM; Gubareva, LV; Loechelt, B; Mishin, VP; Okomo-Adhiambo, M; Tamura, D; Wiedermann, BL | 1 |
| Choi, SH; Hong, SB; Huh, JW; Koh, Y; Lim, CM; Yoo, JW | 1 |
| Doi, M; Igarashi, M; Ishida, H; Ishigaki, H; Ishii, A; Itoh, Y; Kida, H; Kitagawa, N; Nakamura, S; Nakayama, M; Ogasawara, K; Okamatsu, M; Sakoda, Y; Sasamura, T; Shichinohe, S; Shiohara, M; Tsuchiya, H | 1 |
| Azuma, T; Inoyama, T; Ishiuchi, H; Mino, Y; Sato, T; Tanaka, H; Teranishi, Y; Yamaoka, M; Yamashita, N | 1 |
| Batool, S; Kamal, MA; Kamal, W; Mushtaq, G | 1 |
| Cheong, HJ; Choi, WS; Kim, WJ; Noh, JY; Song, JY | 1 |
| Cai, Y; Chen, W; Fang, X; Farooqui, A; Huang, L; Kelvin, AA; Kelvin, DJ; Khan, A; Lin, P; Liu, Y; Paquette, SG; Su, M; Wu, S; Zeng, T; Zhang, L | 1 |
| Fung, CP; Huang, SF; Perng, DW; Wang, FD | 1 |
| Chen, P; Gao, H; Li, L; Liang, W; Ou, H; Tang, L; Wu, X; Yang, Y; Yu, L; Zhang, Y; Zheng, S | 1 |
| Asai, Y; Hsin, KY; Kamiyoshi, K; Kawaoka, Y; Kitano, H; Matsuoka, Y; Watanabe, T | 1 |
| Fujisaki, S; Kishida, N; Kuwahara, T; Nakamura, K; Odagiri, T; Shimazu, Y; Shimomura, T; Shirakura, M; Takashita, E; Watanabe, S | 1 |
| Furuta, K; Hirabayashi, Y; Isobe, R; Ito, T; Kaneko, N; Kawakami, F; Kawakami, T; Kitano, K; Mimura, Y; Nakazawa, H; Shimazaki, M | 1 |
| Hibino, A; Kondo, H; Masaki, H; Saito, R; Saito, T; Sato, I; Takemae, N; Tanabe, Y; Zaraket, H | 1 |
| Abed, Y; Barbeau, X; Boivin, G; Carbonneau, J; Fage, C; Lagüe, P; Tu, V | 1 |
| Ariza-Heredia, EJ; Chemaly, RF; Shahani, L | 1 |
| Koyfman, A; Long, B; Simon, E | 1 |
| Jwa, H; Kim, YH; Lee, J; Park, JH | 1 |
| Besselaar, TG; Daniels, RS; Fry, A; Gregory, V; Gubareva, LV; Huang, W; Hurt, AC; Jorquera, PA; Lackenby, A; Leang, SK; Lo, J; Meijer, A; Odagiri, T; Pereyaslov, D; Rebelo-de-Andrade, H; Siqueira, MM; Takashita, E; Wang, D; Zhang, W | 1 |
| Baranovich, T; Davis, CT; Gubareva, LV; Guo, Z; Hodges, E; Sleeman, K; Stevens, J; Yang, H | 1 |
| Ahn, SJ; Baek, YH; Chae, HB; Choi, WS; Choi, YK; Govorkova, EA; Hwang, J; Jeong, JH; Kim, CJ; Kim, MH; Kwon, HI; Kwon, JJ; Lloren, KKS; Song, MS; Webby, RJ | 1 |
| Hasegawa, T; Hirotsu, N; Saisho, Y; Shishido, T | 1 |
| Akutsu, Y; Aoyagi, H; Ariga, T; Arioka, H; Azuma, K; Furuyama, H; Hatae, Y; Hazama, K; Inagawa, A; Ishiguro, N; Ishizaka, A; Kaiho, M; Kawamura, N; Kikuta, H; Koike, A; Konno, M; Koseki, N; Kumita, Y; Matsuzono, Y; Morita, K; Murashita, M; Nagano, N; Oba, K; Odagawa, Y; Okamura, A; Sawada, Y; Shibata, M; Shida, S; Tabata, Y; Takada, K; Tobise, C; Togashi, T; Tsubakihara, K; Tsuchida, A; Tsuchiyama, A; Uetsuji, K; Watanabe, T; Yamanaka, T; Yamazaki, S; Yasoshima, K; Yasuda, K; Yoshioka, M | 1 |
| Fushimi, K; Matsui, H; Michihata, N; Miyairi, I; Morisaki, N; Okubo, Y; Shoji, K; Uda, K; Yasunaga, H | 1 |
| Chen, C; Chen, L; Guo, L; Guo, Q; Huang, JA; Mu, C; Wang, J; Xu, H | 1 |
| Scott, LJ | 1 |
| Asai, K; Fujioka, M; Hirata, K; Kimura, T; Kureya, Y; Shinataku, H; Tocino, Y; Yoshi, N | 1 |
| Chen, RC; Guan, WD; Jiang, HM; Li, BF; Li, JW; Wang, WJ; Weng, YC; Yang, ZF; Yuan, Y; Zhong, NS | 1 |
| Butler, J; Farrukee, R; Hurt, AC; Reading, PC | 1 |
| Chen, G; Fan, HW; Han, Y; Huang, J; Li, GW; Li, HL; Li, LZ; Li, TS; Li, XW; Liu, SM; Liu, W; Lu, QF; Lu, WZ; Su, ZQ; Wang, SY; Wang, Y; Wu, H; Yao, HY; Ye, WX; Zhang, WH; Zhu, GF | 1 |
| Chi, Y; Cui, L; Ge, Y; Min, X; Shi, Z; Wu, B; Wu, T; Zhao, K; Zhu, F; Zhu, X | 1 |
| Donaldson, EF; Donnelly, RP; Ilyushina, NA; Ince, WL; Komatsu, TE; Lee, N; O'Rear, JJ | 1 |
| Mikurova, AV; Skvortsov, VS | 1 |
| Bao, J; Chen, R; Chen, Y; Li, Y; Liu, S; Ma, J; Shen, B; Shen, W; Vijaykrishna, D; Wang, W; Wang, X; Wang, Y; Wu, W; Wu, X; Xie, F; Yu, F; Zhao, Z; Zheng, S; Zhou, T; Zou, Q | 1 |
| Chen, JY; Lai, CC; Wang, HH; Wei, SK; Weng, TS | 1 |
| Miyazaki, C; Momoi, MY; Ohkusa, Y; Okabe, N; Sugawara, T; Taniguchi, K | 1 |
| Fujisaki, S; Harada, N; Hino, M; Kakeya, H; Koh, H; Nakamae, H; Nanno, S; Okamura, H; Shibata, W; Takashita, E; Yamada, K | 1 |
| Bando, T; Kato, M; Saisho, Y; Tanaka, H | 2 |
| Dugas, AF; Hsieh, YH; LoVecchio, F; McBryde, B; Ricketts, EP; Rothman, RE; Saliba-Shaw, K | 1 |
| Bando, T; Chong, Y; Ikematsu, H; Iwaki, N; Kashiwagi, S; Kawai, N; Tani, N | 1 |
17 review(s) available for cyclopentane and oseltamivir
| Article | Year |
|---|---|
[Peramivir. A new and potent neuraminidase inhibitor for the treatment of influenza].
Topics: Acids, Carbocyclic; Amino Acid Substitution; Animals; Antiviral Agents; Binding Sites; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopentanes; Drug Evaluation, Preclinical; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Mice; Molecular Structure; Neuraminidase; Orthomyxoviridae; Oseltamivir; Point Mutation; Viral Proteins | 2006 |
Neuraminidase inhibitor resistance in influenza viruses.
Topics: Acids, Carbocyclic; Adult; Animals; Antiviral Agents; Catalytic Domain; Child; Clinical Trials as Topic; Cyclopentanes; Drug Administration Schedule; Enzyme Inhibitors; Guanidines; Humans; Immunocompromised Host; Influenza A Virus, H5N1 Subtype; Influenza, Human; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Seasons; Sentinel Surveillance; Viral Proteins; Virulence; Zanamivir | 2007 |
Targeting pandemic influenza: a primer on influenza antivirals and drug resistance.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Disease Outbreaks; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Models, Biological; Oseltamivir; Recombinant Fusion Proteins; Zanamivir | 2010 |
Peramivir and its use in H1N1 influenza.
Topics: Acids, Carbocyclic; Antiviral Agents; Clinical Trials as Topic; Cyclopentanes; Emergencies; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza, Human; Oseltamivir; United States; United States Food and Drug Administration | 2010 |
[Current anti-influenza virus chemotherapy].
Topics: Acids, Carbocyclic; Amantadine; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Drug Utilization; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Infusions, Intravenous; Japan; Oseltamivir; Pandemics; Zanamivir | 2010 |
Treatment options for H5N1: lessons learned from the H1N1 pandemic.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Disease Outbreaks; Drug Resistance, Viral; Guanidines; Humans; Immunocompromised Host; Influenza A Virus, H5N1 Subtype; Influenza, Human; Oseltamivir; Pneumonia, Viral; Pyrans; Severity of Illness Index; Sialic Acids; Zanamivir | 2010 |
[Research progress of anti-influenza virus agents].
Topics: Acids, Carbocyclic; Amantadine; Antiviral Agents; Cyclopentanes; Guanidines; Humans; Indoles; Influenza, Human; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pyrrolidines; Rimantadine; Structure-Activity Relationship; Viral Matrix Proteins; Zanamivir | 2010 |
Recent advances in neuraminidase inhibitor development as anti-influenza drugs.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Benzoic Acid; Cyclopentanes; Drug Design; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza, Human; Models, Molecular; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Zanamivir | 2012 |
[Drug resistance of influenza viruses].
Topics: Acids, Carbocyclic; Amantadine; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A virus; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Viral Matrix Proteins; Zanamivir | 2012 |
Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Viral Proteins; Zanamivir | 2013 |
Optimizing antiviral therapy for influenza: understanding the evidence.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; RNA-Dependent RNA Polymerase; Sialic Acids; Viral Matrix Proteins; Viral Proteins; Zanamivir | 2015 |
Antiviral therapy in seasonal influenza and 2009 H1N1 pandemic influenza: Korean experiences and perspectives.
Topics: Acids, Carbocyclic; Amides; Antiviral Agents; Clinical Trials as Topic; Cyclopentanes; Drug Resistance, Viral; Guanidines; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pyrans; Pyrazines; Republic of Korea; Sialic Acids; Zanamivir | 2015 |
Antiviral therapy for respiratory viral infections in immunocompromised patients.
Topics: Acids, Carbocyclic; Amantadine; Antiviral Agents; Coronavirus Infections; Cyclopentanes; Guanidines; Humans; Immunocompromised Host; Influenza, Human; Oseltamivir; Palivizumab; Paramyxoviridae Infections; Picornaviridae Infections; Respiratory Syncytial Virus Infections; Respiratory Tract Infections; Ribavirin; Zanamivir | 2017 |
Clinical Mimics: An Emergency Medicine-Focused Review of Influenza Mimics.
Topics: Acids, Carbocyclic; Aged; Aged, 80 and over; Antiviral Agents; Child, Preschool; Cyclopentanes; Emergency Medicine; Guanidines; Humans; Infant; Influenza, Human; Middle Aged; Oseltamivir; Risk Factors; United States; Zanamivir | 2017 |
Comparison of Efficacy of Intravenous Peramivir and Oral Oseltamivir for the Treatment of Influenza: Systematic Review and Meta-Analysis.
Topics: Acids, Carbocyclic; Administration, Intravenous; Administration, Oral; Antiviral Agents; Cyclopentanes; Guanidines; Humans; Influenza, Human; Odds Ratio; Oseltamivir; Publication Bias; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome | 2017 |
Peramivir: A Review in Uncomplicated Influenza.
Topics: Acids, Carbocyclic; Administration, Intravenous; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Treatment Outcome | 2018 |
A Meta-Analysis Comparing the Efficacy and Safety of Peramivir with Other Neuraminidase Inhibitors for Influenza Treatment.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Observational Studies as Topic; Oseltamivir; Randomized Controlled Trials as Topic | 2020 |
11 trial(s) available for cyclopentane and oseltamivir
| Article | Year |
|---|---|
Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection.
Topics: Acids, Carbocyclic; Administration, Oral; Adult; Aged; Aged, 80 and over; Antiviral Agents; Cyclopentanes; Double-Blind Method; Drug Administration Schedule; Female; Guanidines; Humans; Influenza, Human; Injections, Intravenous; Male; Middle Aged; Oseltamivir; Young Adult | 2011 |
Absence of pharmacokinetic interaction between intravenous peramivir and oral oseltamivir or rimantadine in humans.
Topics: Acids, Carbocyclic; Administration, Intravenous; Administration, Oral; Adult; Antiviral Agents; Cross-Over Studies; Cyclopentanes; Drug Interactions; Female; Guanidines; Humans; Male; Middle Aged; Oseltamivir; Rimantadine; Young Adult | 2012 |
Clinical effectiveness of neuraminidase inhibitors--oseltamivir, zanamivir, laninamivir, and peramivir--for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan.
Topics: Acids, Carbocyclic; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Disease Outbreaks; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Japan; Male; Neuraminidase; Oseltamivir; Treatment Outcome; Zanamivir | 2012 |
A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults.
Topics: Acids, Carbocyclic; Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antiviral Agents; Cyclopentanes; Female; Guanidines; Hospitalization; Humans; Influenza A virus; Influenza, Human; Inhibitory Concentration 50; Male; Microbial Sensitivity Tests; Middle Aged; Oseltamivir; Risk Factors; Seasons; Treatment Outcome; Viral Load | 2013 |
Clinical effects of oseltamivir, zanamivir, laninamivir and peramivir on seasonal influenza infection in outpatients in Japan during the winter of 2012-2013.
Topics: Acids, Carbocyclic; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Enzyme Inhibitors; Female; Guanidines; Humans; Infant; Influenza, Human; Japan; Male; Middle Aged; Neuraminidase; Oseltamivir; Outpatients; Pyrans; Sialic Acids; Time Factors; Treatment Outcome; Young Adult; Zanamivir | 2013 |
Clinical efficacy of laninamivir and peramivir in patients with seasonal influenza: a randomized clinical trial.
Topics: Acids, Carbocyclic; Adult; Antiviral Agents; Cyclopentanes; Female; Guanidines; Humans; Influenza, Human; Japan; Male; Middle Aged; Oseltamivir; Pyrans; Sialic Acids; Treatment Outcome; Zanamivir | 2017 |
Clinical and virologic effects of four neuraminidase inhibitors in influenza A virus-infected children (aged 4-12 years): an open-label, randomized study in Japan.
Topics: Acids, Carbocyclic; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Female; Guanidines; Humans; Influenza A virus; Influenza, Human; Japan; Male; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Time Factors; Treatment Outcome; Zanamivir | 2018 |
[A randomized controlled study of peramivir, oseltamivir and placebo in patients with mild influenza].
Topics: Acids, Carbocyclic; Adolescent; Adult; Aged; Antiviral Agents; Cyclopentanes; Double-Blind Method; Guanidines; Humans; Influenza, Human; Middle Aged; Oseltamivir; Treatment Outcome; Young Adult | 2019 |
Effect of peramivir on respiratory symptom improvement in patients with influenza virus infection and pre-existing chronic respiratory disease: Findings of a randomized, open-label study.
Topics: Acids, Carbocyclic; Antiviral Agents; Comorbidity; Cyclopentanes; Female; Guanidines; Humans; Influenza, Human; Male; Neuraminidase; Oseltamivir; Respiratory Tract Diseases; Treatment Outcome | 2021 |
Intravenous peramivir vs oral oseltamivir in high-risk emergency department patients with influenza: Results from a pilot randomized controlled study.
Topics: Acids, Carbocyclic; Adult; Antiviral Agents; Cyclopentanes; Emergency Service, Hospital; Guanidines; Humans; Influenza, Human; Oseltamivir; Pilot Projects; Treatment Outcome | 2021 |
Improvement of respiratory symptoms and health-related quality of life with peramivir in influenza patients with chronic respiratory disease: Additional outcomes of a randomized, open-label study.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Guanidines; Humans; Influenza, Human; Oseltamivir; Quality of Life; Treatment Outcome | 2021 |
105 other study(ies) available for cyclopentane and oseltamivir
| Article | Year |
|---|---|
In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201.
Topics: Acetamides; Acids, Carbocyclic; Animals; Antiviral Agents; Cyclopentanes; Disease Models, Animal; Female; Guanidines; Influenza A virus; Influenza B virus; Lung; Mice; Mice, Inbred C57BL; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Respiratory Function Tests; Ribavirin; Virus Replication | 2001 |
Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir.
Topics: Acetamides; Acids, Carbocyclic; Administration, Intranasal; Administration, Oral; Animals; Antiviral Agents; Cyclopentanes; Enzyme Inhibitors; Female; Guanidines; Inhibitory Concentration 50; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Sialic Acids; Species Specificity; Survival Analysis; Time Factors; Zanamivir | 2001 |
Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses.
Topics: Acetamides; Acids, Carbocyclic; Animals; Antiviral Agents; Body Weight; Brain; Cyclopentanes; Disease Models, Animal; Dogs; Female; Guanidines; Influenza A virus; Influenza A Virus, H5N1 Subtype; Influenza A Virus, H9N2 Subtype; Lung; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Sialic Acids; Treatment Outcome; Virus Replication; Zanamivir | 2001 |
Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay.
Topics: Acetamides; Acids, Carbocyclic; Animals; Antiviral Agents; Cyclopentanes; Dogs; Drug Resistance, Viral; Edetic Acid; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2002 |
Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.
Topics: Acetamides; Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Microbial; Enzyme Inhibitors; Guanidines; Influenza A virus; Influenza B virus; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pyrans; Sialic Acids; Substrate Specificity; Zanamivir | 2001 |
Accumulation of defective neuraminidase (NA) genes by influenza A viruses in the presence of NA inhibitors as a marker of reduced dependence on NA.
Topics: Acetamides; Acids, Carbocyclic; Animals; Cell Line; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza, Human; Microbial Sensitivity Tests; Molecular Sequence Data; Neuraminidase; Oseltamivir; Viral Plaque Assay | 2002 |
Oral administration of cyclopentane neuraminidase inhibitors protects ferrets against influenza virus infection.
Topics: Acetamides; Acids, Carbocyclic; Animals; Antiviral Agents; Area Under Curve; Body Temperature; Cell Count; Cyclopentanes; Enzyme Inhibitors; Ferrets; Guanidines; Half-Life; Hemagglutination Inhibition Tests; Influenza A virus; Lung; Male; Nasal Cavity; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir | 2002 |
Structural studies of the resistance of influenza virus neuramindase to inhibitors.
Topics: Acetamides; Acids, Carbocyclic; Alphainfluenzavirus; Antiviral Agents; Crystallography, X-Ray; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Models, Molecular; Mutation; Neuraminidase; Oseltamivir; Protein Binding; Pyrans; Sialic Acids; Zanamivir | 2002 |
Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors.
Topics: Acetamides; Acids, Carbocyclic; Canada; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Fluorometry; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Inhibitory Concentration 50; Luminescent Measurements; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2002 |
Identification of a human influenza type B strain with reduced sensitivity to neuraminidase inhibitor drugs.
Topics: Acetamides; Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Infant; Influenza B virus; Luminescent Measurements; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2004 |
A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus.
Topics: Acetamides; Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Inhibitory Concentration 50; Mutation; Neuraminidase; Oseltamivir; Pyrans; Recombination, Genetic; Sialic Acids; Zanamivir | 2004 |
Comparison of the anti-influenza virus activity of cyclopentane derivatives with oseltamivir and zanamivir in vivo.
Topics: Acetamides; Acids, Carbocyclic; Administration, Intranasal; Administration, Oral; Animals; Antiviral Agents; Cyclopentanes; Dose-Response Relationship, Drug; Guanidines; Mice; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Sialic Acids; Structure-Activity Relationship; Survival Rate; Treatment Outcome; Zanamivir | 2005 |
Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient.
Topics: Acetamides; Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; Baculoviridae; Base Sequence; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Female; Guanidines; Humans; Infant; Influenza B virus; Influenza, Human; Inhibitory Concentration 50; Microbial Sensitivity Tests; Molecular Sequence Data; Neuraminidase; Oseltamivir; Pyrans; Recombinant Proteins; Sialic Acids; Zanamivir | 2006 |
Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child.
Topics: Acids, Carbocyclic; Antiviral Agents; Child; Cyclopentanes; Drug Resistance, Multiple; Drug Resistance, Viral; Guanidines; Humans; Immunocompromised Host; Influenza A Virus, H3N2 Subtype; Mutation; Oseltamivir; Zanamivir | 2006 |
Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes.
Topics: Acids, Carbocyclic; Amantadine; Animals; Antiviral Agents; Base Sequence; Birds; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2007 |
Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Animals; Antiviral Agents; Cell Line; Cyclopentanes; Dogs; Drug Resistance, Viral; Guanidines; Hemagglutinin Glycoproteins, Influenza Virus; Influenza A Virus, H1N1 Subtype; Mutation; Mutation, Missense; Neuraminidase; Oseltamivir; Selection, Genetic; Sequence Deletion; Viral Proteins; Zanamivir | 2007 |
Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Cell Line; Cyclopentanes; Drug Resistance, Multiple, Viral; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Male; Mice; Mice, Inbred BALB C; Mutation; Neuraminidase; Oseltamivir; Viral Proteins; Zanamivir | 2006 |
Understanding of known drug-target interactions in the catalytic pocket of neuraminidase subtype N1.
Topics: Acids, Carbocyclic; Algorithms; Antiviral Agents; Binding Sites; Catalysis; Computer Simulation; Cyclopentanes; Databases, Protein; Guanidines; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Influenza A Virus, H5N1 Subtype; Inhibitory Concentration 50; Ligands; Models, Molecular; Molecular Conformation; N-Acetylneuraminic Acid; Neuraminidase; Oseltamivir; Pressure; Protein Binding; Protein Structure, Secondary; Static Electricity; Temperature; Thermodynamics; Time Factors; Water; Zanamivir | 2008 |
Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1).
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Cyclopentanes; Ferrets; Guanidines; Influenza A Virus, H5N1 Subtype; Injections, Intramuscular; Lung; Mice; Orthomyxoviridae Infections; Oseltamivir; Survival Analysis; Treatment Outcome | 2008 |
Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; Asia, Southeastern; Cluster Analysis; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Oceania; Oseltamivir; Phylogeny; RNA, Viral; Sequence Analysis, DNA; Sequence Homology; South Africa; Viral Proteins; Zanamivir | 2009 |
Dynamic behavior of avian influenza A virus neuraminidase subtype H5N1 in complex with oseltamivir, zanamivir, peramivir, and their phosphonate analogues.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Cyclopentanes; Drug Design; Enzyme Inhibitors; Guanidines; Influenza A Virus, H5N1 Subtype; Molecular Conformation; Molecular Dynamics Simulation; Neuraminidase; Organophosphonates; Oseltamivir; Time Factors; Zanamivir | 2009 |
Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Animals; Antiviral Agents; Cell Line; Cyclopentanes; Dogs; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Inhibitory Concentration 50; Molecular Sequence Data; Mutation, Missense; Neuraminidase; Oseltamivir; RNA, Viral; Sequence Analysis, DNA; Viral Proteins; Zanamivir | 2010 |
Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Female; Guanidines; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Oseltamivir; RNA, Viral; Selection, Genetic; Sequence Analysis, DNA; Young Adult | 2010 |
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
Topics: Acids, Carbocyclic; Animals; Cell Line; Cyclopentanes; Dogs; Enzyme Assays; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Inhibitory Concentration 50; Neuraminidase; Oseltamivir; Zanamivir | 2010 |
Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Cell Line; Cyclopentanes; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Interactions; Drug Therapy, Combination; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir | 2010 |
Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Birds; Catalytic Domain; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza in Birds; Influenza, Human; Models, Molecular; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Protein Conformation; Species Specificity; Swine; Swine Diseases; Viral Proteins; Zanamivir | 2010 |
Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
Topics: Acids, Carbocyclic; Antiviral Agents; Crystallography, X-Ray; Cyclopentanes; Drug Resistance, Viral; Guanidines; Hydrogen Bonding; Influenza B virus; Models, Molecular; Molecular Structure; Mutation; Neuraminidase; Oseltamivir; Protein Binding; Zanamivir | 2010 |
Synergistic effects in the designs of neuraminidase ligands: analysis from docking and molecular dynamics studies.
Topics: Acids, Carbocyclic; Benzoates; Catalytic Domain; Cyclohexenes; Cyclopentanes; Drug Design; Guanidines; Humans; Hydrogen Bonding; Influenza, Human; Inhibitory Concentration 50; Ligands; Models, Molecular; Molecular Dynamics Simulation; Molecular Structure; Neuraminidase; Orthomyxoviridae; Oseltamivir; Protein Binding; Static Electricity; Structure-Activity Relationship; Thermodynamics | 2010 |
Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Fatal Outcome; Guanidines; Hematopoietic Stem Cell Transplantation; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Mutation; Neuraminidase; Oseltamivir | 2010 |
Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Oseltamivir; Pyrrolidines; Recombination, Genetic; Viral Plaque Assay; Viral Proteins; Virus Replication; Zanamivir | 2011 |
Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
Topics: Acids, Carbocyclic; Adamantane; Amino Acid Substitution; Animals; Antiviral Agents; Cell Line; Cyclopentanes; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Oseltamivir; Pyrans; Pyrrolidines; Sialic Acids; Viral Plaque Assay; Zanamivir | 2010 |
Zanamivir, at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 influenza virus in an in vitro hollow-fiber infection model system.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Cell Line; Cyclopentanes; Dogs; Drug Resistance, Viral; Guanidines; Influenza A Virus, H1N1 Subtype; Oseltamivir; Zanamivir | 2011 |
Characterization of the binding affinities of peramivir and oseltamivir carboxylate to the neuraminidase enzyme.
Topics: Acids, Carbocyclic; Antiviral Agents; Buffers; Cyclopentanes; Drug Combinations; Drug Interactions; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Protein Binding; Solutions; Spectrometry, Fluorescence; Viral Proteins | 2011 |
Postpartum pharmacokinetics of peramivir in the treatment of 2009 H1N1 influenza.
Topics: Acids, Carbocyclic; Adult; Antiviral Agents; Cesarean Section; Cyclopentanes; Disease Outbreaks; Female; Guanidines; Humans; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Severity of Illness Index; Treatment Outcome | 2011 |
Real time enzyme inhibition assays provide insights into differences in binding of neuraminidase inhibitors to wild type and mutant influenza viruses.
Topics: Acids, Carbocyclic; Binding, Competitive; Cyclopentanes; Enzyme Assays; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N1 Subtype; Inhibitory Concentration 50; Kinetics; Mutation; N-Acetylneuraminic Acid; Neuraminidase; Orthomyxoviridae; Oseltamivir; Protein Binding; Substrate Specificity; Time Factors; Viral Proteins; Zanamivir | 2011 |
Influenza B viruses with mutation in the neuraminidase active site, North Carolina, USA, 2010-11.
Topics: Acids, Carbocyclic; Adolescent; Adult; Antiviral Agents; Catalytic Domain; Child; Child, Preschool; Cyclopentanes; Drug Resistance, Viral; Guanidines; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Infant; Influenza B virus; Influenza, Human; Microbial Sensitivity Tests; Middle Aged; Mutation; Neuraminidase; North Carolina; Oseltamivir; Phylogeny; Polymorphism, Single Nucleotide; Young Adult | 2011 |
Pharmacokinetic assessment of peramivir in a hospitalized adult undergoing continuous venovenous hemofiltration.
Topics: Acids, Carbocyclic; Acute Kidney Injury; Adolescent; Cyclopentanes; Guanidines; Hemofiltration; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir | 2011 |
Drugs: Lines of defence.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2011 |
Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Animals; Antiviral Agents; Cell Line; Cyclopentanes; Dogs; Drug Resistance, Viral; Ferrets; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Inhibitory Concentration 50; Male; Models, Molecular; Mutagenesis, Site-Directed; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Pandemics; Reverse Genetics; Viral Proteins; Virus Replication; Zanamivir | 2012 |
In vitro neuraminidase inhibitory activities of four neuraminidase inhibitors against influenza viruses isolated in the 2010-2011 season in Japan.
Topics: Acids, Carbocyclic; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Enzyme Inhibitors; Female; Guanidines; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Inhibitory Concentration 50; Japan; Male; Microbial Sensitivity Tests; Middle Aged; Neuraminidase; Oseltamivir; Zanamivir | 2012 |
Recovery of influenza B virus with the H273Y point mutation in the neuraminidase active site from a human patient.
Topics: Acids, Carbocyclic; Adult; Antiviral Agents; Catalytic Domain; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza B virus; Influenza, Human; Male; Molecular Sequence Data; Mutation, Missense; Neuraminidase; Oseltamivir; Point Mutation; RNA, Viral; Sequence Analysis, DNA; Zanamivir | 2012 |
In vitro passaging of a pandemic H1N1/09 virus selects for viruses with neuraminidase mutations conferring high-level resistance to oseltamivir and peramivir, but not to zanamivir.
Topics: Acids, Carbocyclic; Animals; Cells, Cultured; Cyclopentanes; Dogs; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Molecular Sequence Data; Mutation, Missense; Neuraminidase; Oseltamivir; RNA, Viral; Selection, Genetic; Sequence Analysis, DNA; Serial Passage; Zanamivir | 2012 |
Therapeutic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H275Y neuraminidase mutation.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Female; Guanidines; Influenza A Virus, H1N1 Subtype; Injections, Intramuscular; Mice; Mice, Inbred BALB C; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Treatment Outcome; Viral Proteins | 2012 |
[Clinical efficiency in children treated with intravenous drip infusion of peramivir].
Topics: Acids, Carbocyclic; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Guanidines; Humans; Infant; Infant, Newborn; Influenza A virus; Influenza B virus; Influenza, Human; Infusions, Intravenous; Oseltamivir; Retrospective Studies; Time Factors; Treatment Outcome | 2011 |
A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Catalytic Domain; Cyclopentanes; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; HEK293 Cells; Humans; Influenza B virus; Madin Darby Canine Kidney Cells; Models, Molecular; Mutation; Neuraminidase; Oseltamivir; Protein Conformation; Pyrans; Sialic Acids; Viral Proteins; Zanamivir | 2012 |
Efficacy of repeated intravenous injection of peramivir against influenza A (H1N1) 2009 virus infection in immunosuppressed mice.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Body Weight; Cyclopentanes; Cyclophosphamide; Drug Administration Schedule; Female; Guanidines; Immunosuppressive Agents; Influenza A Virus, H1N1 Subtype; Injections, Intravenous; Lung; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; Phosphorous Acids; Survival Analysis; Treatment Outcome | 2013 |
Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season.
Topics: Acids, Carbocyclic; Africa; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Global Health; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Neuraminidase; Oceania; Oseltamivir; Pyrans; Seasons; Sentinel Surveillance; Sialic Acids; South America; Zanamivir | 2013 |
Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance.
Topics: Acids, Carbocyclic; Aged; Aged, 80 and over; Antiviral Agents; Base Sequence; China; Cyclopentanes; Drug Resistance, Viral; Female; Guanidines; Humans; Influenza A virus; Influenza, Human; Male; Middle Aged; Molecular Sequence Data; Oseltamivir; RNA, Viral; Virus Shedding | 2013 |
Characterization of neuraminidase inhibitor-resistant influenza A(H1N1)pdm09 viruses isolated in four seasons during pandemic and post-pandemic periods in Japan.
Topics: Acids, Carbocyclic; Alleles; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Genotype; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Neuraminidase; Oseltamivir; Pandemics; RNA, Viral; Sequence Analysis, DNA; Viral Proteins | 2013 |
Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Cell Line; Cyclopentanes; DNA Mutational Analysis; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Inhibitory Concentration 50; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Oseltamivir; Viral Proteins; Zanamivir | 2013 |
Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; China; Coinfection; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Oseltamivir; Viral Plaque Assay; Viral Proteins; Zanamivir | 2013 |
Inhibition of novel reassortant avian influenza H7N9 virus infection in vitro with three antiviral drugs, oseltamivir, peramivir and favipiravir.
Topics: Acids, Carbocyclic; Amides; Animals; Antiviral Agents; Cyclopentanes; Dogs; Drug Resistance, Viral; Guanidines; Influenza A Virus, H7N9 Subtype; Madin Darby Canine Kidney Cells; Oseltamivir; Pyrazines; Reassortant Viruses | 2014 |
Insights into susceptibility of antiviral drugs against the E119G mutant of 2009 influenza A (H1N1) neuraminidase by molecular dynamics simulations and free energy calculations.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Influenza A Virus, H1N1 Subtype; Molecular Dynamics Simulation; Mutant Proteins; Neuraminidase; Oseltamivir; Protein Binding; Protein Conformation; Static Electricity; Thermodynamics; Viral Proteins; Zanamivir | 2013 |
Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Animals; Antiviral Agents; Cell Culture Techniques; Cyclopentanes; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Gene Expression; Guanidines; Humans; Influenza A Virus, H3N2 Subtype; Inhibitory Concentration 50; Madin Darby Canine Kidney Cells; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Viral Load; Viral Proteins; Virus Replication; Zanamivir | 2013 |
Therapy of H7N9 pneumonia: current perspectives.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Pulmonary Ventilation; Zanamivir | 2013 |
Neuraminidase inhibitors for critically ill children with influenza.
Topics: Acids, Carbocyclic; Adolescent; Betainfluenzavirus; California; Child; Child, Preschool; Critical Care; Critical Illness; Cyclopentanes; Drug Administration Schedule; Enzyme Inhibitors; Guanidines; Hospitalization; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Logistic Models; Multivariate Analysis; Neuraminidase; Odds Ratio; Oseltamivir; Pandemics; Population Surveillance; Treatment Outcome; Zanamivir | 2013 |
Computational assay of H7N9 influenza neuraminidase reveals R292K mutation reduces drug binding affinity.
Topics: Acids, Carbocyclic; Antiviral Agents; Computational Biology; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Molecular Dynamics Simulation; Mutation; Neuraminidase; Oseltamivir; Protein Binding; Zanamivir | 2013 |
A community cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013.
Topics: Acids, Carbocyclic; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; DNA, Viral; Drug Resistance, Viral; Female; Guanidines; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Male; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Neuraminidase; Oseltamivir; Phylogeny; Sequence Analysis, DNA; Treatment Outcome | 2014 |
Antiviral susceptibility of variant influenza A(H3N2)v viruses isolated in the United States from 2011 to 2013.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Cyclopentanes; Dogs; Guanidines; Humans; Influenza A Virus, H3N2 Subtype; Madin Darby Canine Kidney Cells; Oseltamivir; Pyrans; Sialic Acids; United States; Virus Replication; Zanamivir | 2014 |
The effect of intravenous peramivir, compared with oral oseltamivir, on the outcome of post-influenza pneumococcal pneumonia in mice.
Topics: Acids, Carbocyclic; Administration, Intravenous; Administration, Oral; Animals; Antiviral Agents; Chemokine CXCL2; Chemokines; Coinfection; Cyclopentanes; Guanidines; Influenza A Virus, H1N1 Subtype; Interferon-gamma; Interleukin-6; Lung; Male; Mice; Mice, Inbred CBA; Orthomyxoviridae Infections; Oseltamivir; Pneumonia, Pneumococcal; Streptococcus pneumoniae; Survival Analysis; Treatment Outcome; Tumor Necrosis Factor-alpha | 2015 |
Structural analysis of the novel influenza A (H7N9) viral Neuraminidase interactions with current approved neuraminidase inhibitors Oseltamivir, Zanamivir, and Peramivir in the presence of mutation R289K.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Influenza A Virus, H7N9 Subtype; Molecular Docking Simulation; Molecular Dynamics Simulation; Mutation; Neuraminidase; Oseltamivir; Viral Proteins; Zanamivir | 2013 |
Clinical efficacy of peramivir in adult patients with seasonal influenza during the winter of 2012 in Japan.
Topics: Acids, Carbocyclic; Adult; Aged; Aged, 80 and over; Antiviral Agents; Cyclopentanes; Female; Guanidines; Hospitalization; Humans; Influenza A virus; Influenza, Human; Japan; Male; Middle Aged; Oseltamivir; Retrospective Studies; Seasons; Treatment Outcome | 2015 |
Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor.
Topics: Acids, Carbocyclic; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Enzyme Inhibitors; Female; Fever; Guanidines; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pyrans; Severity of Illness Index; Sialic Acids; Time Factors; Treatment Outcome; Viral Proteins; Virus Shedding; Zanamivir | 2015 |
Solid phase assay for comparing reactivation rates of neuraminidases of influenza wild type and resistant mutants after inhibitor removal.
Topics: Acids, Carbocyclic; Cyclopentanes; Enzyme Inhibitors; Guanidines; Kinetics; Mutant Proteins; Neuraminidase; Orthomyxoviridae; Oseltamivir; Protein Binding; Viral Proteins; Zanamivir | 2014 |
Combination effects of peramivir and favipiravir against oseltamivir-resistant 2009 pandemic influenza A(H1N1) infection in mice.
Topics: Acids, Carbocyclic; Amides; Animals; Antiviral Agents; Body Weight; Cyclopentanes; Dogs; Drug Resistance, Viral; Drug Synergism; Drug Therapy, Combination; Female; Guanidines; Influenza A Virus, H1N1 Subtype; Lung; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred DBA; Orthomyxoviridae Infections; Oseltamivir; Pyrazines; Survival Rate | 2014 |
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2014 |
Multiple influenza A (H3N2) mutations conferring resistance to neuraminidase inhibitors in a bone marrow transplant recipient.
Topics: Acids, Carbocyclic; Adult; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Fatal Outcome; Female; Guanidines; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunosuppressive Agents; Influenza A Virus, H3N2 Subtype; Influenza, Human; Leukemia, B-Cell; Models, Molecular; Mutation; Neuraminidase; Oseltamivir; Transplantation, Homologous; Viral Proteins; Zanamivir | 2014 |
In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of influenza virus in the Japanese 2012-2013 season.
Topics: Acids, Carbocyclic; Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Inhibitory Concentration 50; Japan; Madin Darby Canine Kidney Cells; Middle Aged; Neuraminidase; Oseltamivir; Young Adult; Zanamivir | 2015 |
Characterization of human Influenza Viruses in Lebanon during 2010-2011 and 2011-2012 post-pandemic seasons.
Topics: Acids, Carbocyclic; Amantadine; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Lebanon; Microbial Sensitivity Tests; Mutation; Neuraminidase; Oseltamivir; Pandemics; Phylogeny; Pyrans; Sialic Acids; Zanamivir | 2014 |
Profiling and characterization of influenza virus N1 strains potentially resistant to multiple neuraminidase inhibitors.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Cell Line; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Genomic Instability; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Kinetics; Mice; Mutant Proteins; Mutation, Missense; Neuraminidase; Oseltamivir; Viral Proteins; Virulence; Virus Replication; Zanamivir | 2015 |
Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients.
Topics: Acids, Carbocyclic; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Beijing; Cohort Studies; Cyclopentanes; Enzyme Inhibitors; Female; Guanidines; Hong Kong; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Influenza, Human; Male; Middle Aged; Multivariate Analysis; Neuraminidase; Oseltamivir; Pneumonia, Bacterial; Proportional Hazards Models; Prospective Studies; Protective Factors; Respiratory Insufficiency; Retrospective Studies; Risk Factors; Singapore; Superinfection; Young Adult; Zanamivir | 2015 |
Characterization of a large cluster of influenza A(H1N1)pdm09 viruses cross-resistant to oseltamivir and peramivir during the 2013-2014 influenza season in Japan.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Japan; Oseltamivir; Viral Proteins | 2015 |
Influenza A viruses of swine circulating in the United States during 2009-2014 are susceptible to neuraminidase inhibitors but show lineage-dependent resistance to adamantanes.
Topics: Acids, Carbocyclic; Adamantane; Amino Acid Substitution; Animals; Antiviral Agents; Base Sequence; Cyclopentanes; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Genotype; Guanidines; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H1N2 Subtype; Influenza A Virus, H3N2 Subtype; Madin Darby Canine Kidney Cells; Mutation, Missense; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Phenotype; Phylogeny; Swine; Swine Diseases; Time Factors; United States; Viral Proteins; Zanamivir | 2015 |
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; China; Cyclopentanes; Disease Outbreaks; Drug Resistance, Viral; Enzyme Inhibitors; Europe; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Inhibitory Concentration 50; Japan; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Phylogeny; Pyrans; Sialic Acids; Time Factors; United States; World Health Organization; Zanamivir | 2015 |
Intravenous peramivir inhibits viral replication, and leads to bacterial clearance and prevention of mortality during murine bacterial co-infection caused by influenza A(H1N1)pdm09 virus and Streptococcus pneumoniae.
Topics: Acids, Carbocyclic; Administration, Intravenous; Animals; Antiviral Agents; Bacterial Load; Coinfection; Cyclopentanes; Cytokines; Disease Models, Animal; Dogs; Guanidines; Influenza A Virus, H1N1 Subtype; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; Pneumococcal Infections; Streptococcus pneumoniae; Viral Load; Virus Replication | 2015 |
Emergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Immunocompromised Host; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Mutation, Missense; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Viral Proteins; Zanamivir | 2015 |
Peramivir is as effective as oral oseltamivir in the treatment of severe seasonal influenza.
Topics: Acids, Carbocyclic; Administration, Oral; Adult; Aged; Aged, 80 and over; Antiviral Agents; Critical Illness; Cyclopentanes; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Intensive Care Units; Length of Stay; Middle Aged; Organ Dysfunction Scores; Oseltamivir; Retrospective Studies; Seasons; Time Factors; Treatment Outcome; Young Adult | 2015 |
Emergence of H7N9 Influenza A Virus Resistant to Neuraminidase Inhibitors in Nonhuman Primates.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza A Virus, H5N1 Subtype; Influenza A Virus, H7N9 Subtype; Influenza Vaccines; Influenza, Human; Macaca; Mice; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Primates; Vaccination; Viral Proteins; Virus Replication | 2015 |
In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of the influenza virus circulating in the Japanese 2013-2014 season.
Topics: Acids, Carbocyclic; Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Cyclopentanes; Enzyme Inhibitors; Female; Guanidines; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Inhibitory Concentration 50; Japan; Male; Middle Aged; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Time Factors; Young Adult; Zanamivir | 2015 |
Detection of peramivir and laninamivir, new anti-influenza drugs, in sewage effluent and river waters in Japan.
Topics: Acids, Carbocyclic; Antiviral Agents; Cities; Cyclopentanes; Drug Residues; Environmental Monitoring; Guanidines; Japan; Limit of Detection; Oseltamivir; Ozone; Pyrans; Risk Assessment; Rivers; Sewage; Sialic Acids; Water Pollutants, Chemical; Water Purification; Zanamivir | 2015 |
Pharmacophore-Based Virtual Screening for Identification of Novel Neuraminidase Inhibitors and Verification of Inhibitory Activity by Molecular Docking.
Topics: Acids, Carbocyclic; Binding Sites; Cyclopentanes; Databases, Chemical; Glycoside Hydrolase Inhibitors; Guanidines; Influenza A Virus, H5N1 Subtype; Ligands; Molecular Docking Simulation; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Structure-Activity Relationship; Viral Proteins; Zanamivir | 2016 |
Assessment of Antiviral Properties of Peramivir against H7N9 Avian Influenza Virus in an Experimental Mouse Model.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Cyclopentanes; Dogs; Drug Administration Schedule; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza A Virus, H7N9 Subtype; Injections, Intramuscular; Lung; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred C57BL; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Survival Analysis; Treatment Outcome; Viral Load; Viral Proteins; Virus Replication | 2015 |
Effects of corticosteroid and neuraminidase inhibitors on survival in patients with respiratory distress induced by influenza virus.
Topics: Acids, Carbocyclic; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Antiviral Agents; Cyclopentanes; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Metabolic Syndrome; Middle Aged; Neuraminidase; Orthomyxoviridae; Oseltamivir; Respiratory Distress Syndrome; Retrospective Studies; Taiwan; Treatment Outcome | 2017 |
Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for Influenza A (H7N9) infection: a retrospective study.
Topics: Acids, Carbocyclic; Adolescent; Adult; Aged; Antiviral Agents; China; Cyclopentanes; Drug Therapy, Combination; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Respiratory Distress Syndrome; Retrospective Studies; Viral Load; Young Adult | 2016 |
systemsDock: a web server for network pharmacology-based prediction and analysis.
Topics: Acids, Carbocyclic; Cyclopentanes; Guanidines; Humans; Influenza, Human; Internet; Ligands; Molecular Docking Simulation; Orthomyxoviridae; Oseltamivir; Pharmacology; Software; User-Computer Interface | 2016 |
Influenza A(H1N1)pdm09 virus exhibiting enhanced cross-resistance to oseltamivir and peramivir due to a dual H275Y/G147R substitution, Japan, March 2016.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Middle Aged; Mutation; Neuraminidase; Oseltamivir; Treatment Outcome | 2016 |
Persistent Infection of Drug-resistant Influenza A Virus during Chemotherapy for Malignant Lymphoma.
Topics: Acids, Carbocyclic; Aged, 80 and over; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Lymphoma; Male; Mutation; Neuraminidase; Oseltamivir | 2016 |
Community- and hospital-acquired infections with oseltamivir- and peramivir-resistant influenza A(H1N1)pdm09 viruses during the 2015-2016 season in Japan.
Topics: Acids, Carbocyclic; Adolescent; Adult; Aged; Child; Child, Preschool; Community-Acquired Infections; Cross Infection; Cyclopentanes; Drug Resistance, Viral; Female; Genes, Viral; Guanidines; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Male; Middle Aged; Mutation; Oseltamivir; Phylogeny; Seasons; Young Adult | 2017 |
The I427T neuraminidase (NA) substitution, located outside the NA active site of an influenza A(H1N1)pdm09 variant with reduced susceptibility to NA inhibitors, alters NA properties and impairs viral fitness.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Animals; Antiviral Agents; Catalytic Domain; Computer Simulation; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Genetic Fitness; Guanidines; Influenza A Virus, H1N1 Subtype; Inhibitory Concentration 50; Mice; Molecular Dynamics Simulation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Reverse Genetics | 2017 |
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Epidemiological Monitoring; Global Health; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza B virus; Influenza, Human; Inhibitory Concentration 50; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Pyrans; Seasons; Sialic Acids; World Health Organization; Zanamivir | 2017 |
Drug Susceptibility Evaluation of an Influenza A(H7N9) Virus by Analyzing Recombinant Neuraminidase Proteins.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Databases, Genetic; Drug Resistance, Multiple, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Inhibitory Concentration 50; Neuraminidase; Oseltamivir; Protein Conformation; Pyrans; Recombinant Proteins; Sialic Acids; Viral Proteins; Zanamivir | 2017 |
Screening for Neuraminidase Inhibitor Resistance Markers among Avian Influenza Viruses of the N4, N5, N6, and N8 Neuraminidase Subtypes.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Animals; Antiviral Agents; Birds; Cyclopentanes; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza in Birds; Influenza, Human; Madin Darby Canine Kidney Cells; Mutagenesis; Neuraminidase; Orthomyxoviridae; Oseltamivir; Reverse Genetics; Zanamivir | 2018 |
Clinical effectiveness of four neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, and peramivir) for children with influenza A and B in the 2014-2015 to 2016-2017 influenza seasons in Japan.
Topics: Acids, Carbocyclic; Adolescent; Betainfluenzavirus; Child; Child, Preschool; Cyclopentanes; Enzyme Inhibitors; Female; Guanidines; Humans; Infant; Infant, Newborn; Influenza A virus; Influenza, Human; Japan; Male; Neuraminidase; Oseltamivir; Pyrans; Seasons; Sialic Acids; Treatment Outcome; Zanamivir | 2018 |
Trends of neuraminidase inhibitors use in children with influenza related respiratory infections.
Topics: Acids, Carbocyclic; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Drug Utilization; Enzyme Inhibitors; Female; Guanidines; Hospitalization; Humans; Infant; Influenza, Human; Japan; Male; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2018 |
A study on mother-to-fetus/infant transmission of influenza A(H7N9) virus: Two case reports and a review of literature.
Topics: Acids, Carbocyclic; Adult; Cyclopentanes; Enzyme Inhibitors; Fatal Outcome; Female; Fetal Death; Fetus; Guanidines; Humans; Infant; Influenza A Virus, H7N9 Subtype; Influenza, Human; Maternal-Fetal Exchange; Mothers; Neuraminidase; Oseltamivir; Pregnancy; Secondary Prevention; Treatment Outcome | 2018 |
Comparison of the Clinical Courses of Patients with Influenza after Neuraminidase Inhibitors Treatment: A Postcard Survey of the 2013-2014 Influenza Season in Osaka.
Topics: Acids, Carbocyclic; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Disease Outbreaks; Enzyme Inhibitors; Female; Guanidines; Humans; Infant; Influenza, Human; Japan; Male; Middle Aged; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Surveys and Questionnaires; Treatment Outcome; Zanamivir | 2016 |
Veno-venous extracorporeal membrane oxygenation for patient with a history of open cholecystectomy and acute respiratory distress syndrome caused by coinfection of avian influenza A (H7N9) and Epstein-Barr virus.
Topics: Acids, Carbocyclic; Anti-Bacterial Agents; Antiviral Agents; Cholecystectomy; Cyclopentanes; Extracorporeal Membrane Oxygenation; Female; Guanidines; Herpesvirus 4, Human; Humans; Influenza A Virus, H7N9 Subtype; Middle Aged; Oseltamivir; Respiratory Distress Syndrome | 2019 |
Characterization of substitutions in the neuraminidase of A(H7N9) influenza viruses selected following serial passage in the presence of different neuraminidase inhibitors.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Animals; Antiviral Agents; Cyclopentanes; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; HEK293 Cells; Humans; Influenza A Virus, H7N9 Subtype; Madin Darby Canine Kidney Cells; Neuraminidase; Oseltamivir; Pyrans; Serial Passage; Sialic Acids; Species Specificity; Viral Proteins; Zanamivir | 2019 |
The evolution and characterization of influenza A(H7N9) virus under the selective pressure of peramivir.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Animals; Antiviral Agents; Cyclopentanes; Dogs; Drug Resistance, Viral; Evolution, Molecular; Gene Expression; Guanidines; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Madin Darby Canine Kidney Cells; Neuraminidase; Oseltamivir; Viral Load; Viral Proteins; Virus Replication | 2019 |
Influenza A virus hemagglutinin mutations associated with use of neuraminidase inhibitors correlate with decreased inhibition by anti-influenza antibodies.
Topics: Acids, Carbocyclic; Antiviral Agents; Cell Line; Crystallography, X-Ray; Cyclopentanes; Drug Resistance, Viral; Epithelial Cells; Epitopes; Guanidines; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A Virus, H1N1 Subtype; Mutant Proteins; Mutation, Missense; Neuraminidase; Oseltamivir; Protein Conformation; Selection, Genetic; Viral Proteins; Virus Replication; Zanamivir | 2019 |
[The model of prediction of the inhibition of neuraminidases of influenza A and B based on a reduced set of energy terms].
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Enzyme Inhibitors; Guanidines; Influenza A virus; Influenza B virus; Neuraminidase; Oseltamivir; Viral Proteins; Zanamivir | 2019 |
Influenza A-associated severe pneumonia in hospitalized patients: Risk factors and NAI treatments.
Topics: Acids, Carbocyclic; Antiviral Agents; China; Cyclopentanes; Epidemics; Female; Guanidines; Humans; Influenza A virus; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Pneumonia, Viral; Proportional Hazards Models; Retrospective Studies; Risk Factors | 2020 |
Association of moderately abnormal behavior and administered neuraminidase inhibitors.
Topics: Acids, Carbocyclic; Adolescent; Antiviral Agents; Child; Cyclopentanes; Enzyme Inhibitors; Guanidines; Humans; Illness Behavior; Influenza, Human; Japan; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Young Adult; Zanamivir | 2020 |
Successful treatment with baloxavir marboxil of a patient with peramivir-resistant influenza A/H3N2 with a dual E119D/R292K substitution after allogeneic hematopoietic cell transplantation: a case report.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Dibenzothiepins; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Middle Aged; Morpholines; Mutation; Neuraminidase; Oseltamivir; Oxazines; Pyridines; Pyridones; Thiepins; Transplantation, Homologous; Treatment Outcome; Triazines; Viral Proteins | 2020 |
Susceptibility of epidemic viruses to neuraminidase inhibitors and treatment-emergent resistance in the Japanese 2019-20 influenza season.
Topics: Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Japan; Neuraminidase; Oseltamivir; Prospective Studies; Seasons | 2022 |